Speciality: Rheumatology
Description:
A warm welcome to all the medical professionals in this interesting session on an overview of juvenile idiopathic arthritis and the role of etanercept in juvenile idiopathic arthritis.
Rheumatoid arthritis is an autoimmune disease that usually affects a majority of the adult population, however, if it occurs in children under 16 is called juvenile idiopathic arthritis (JIA). It can cause severe pain due to the stiffness of the joints and affect the mobility of the joints.
A detailed discussion is provided on the occurrence and management of juvenile idiopathic arthritis in children. JIA can cause serious complications, like growth problems, joint damage, and eye inflammation.
TNF alpha inhibitors and JAK inhibitors play a key role in altering immune responses in such cases. Etanercept, a TNF-inhibiting drug, can be an advanced treatment option in managing juvenile idiopathic arthritis. These are mostly used for people with different types of rheumatic diseases.
Thus, listen to the webinar, grab the knowledge that is shared, and follow HiDoc for more such exciting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
More Positive Survival Data in Lung Cancer With Perioperative Therapy
2.
Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy
3.
Study finds 10% of pediatric blood cancers may stem from medical imaging radiation
4.
For the creation of cutting-edge targeted radionuclide therapies in oncology, Bayer and Bicycle Therapeutics work together.
5.
Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.
1.
Case Study: Artificial Intelligence in Early Cancer Detection
2.
Understanding Acute Intermittent Porphyria: Symptoms, Diagnosis and Treatment
3.
What is Mullerian and How Does it Affect Your Health
4.
AI in Cancer Care: Transforming Research & Treatment with Deep Learning Technologies
5.
Is p53 the Missing Puzzle Piece? Exploring Its Polymorphisms in Cervical Cancer Risk
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Should We Use DARA Up Front As First-Line Therapy in MM?
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation